EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Integrated bioinformatics and in vitro analyses identify BHLHE40 as a candidate regulator associated with senescence-like growth arrest in multiple myeloma

Yuanyuan Pei, Pinhao Li, Zhenhong Pu, Dan Xu, Wenxiu Yang

Frontiers in Oncology · 11.11.2026 · 16

DOI: 10.3389/fonc.2026.1989759 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Oncology, online erschienen am 11.11.2026. Verfasst von Yuanyuan Pei und 4 weiteren Autor:innen. Die Arbeit nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Multiple myeloma exhibits significant molecular heterogeneity and is continuously influenced by the bone marrow immune microenvironment. Cellular senescence can restrict tumor expansion through stable growth arrest, while also remodeling the local microenvironment via the senescence-associated secretory phenotype.

Methods

By integrating the GSE6477 and GSE72213 microarray cohorts, candidate genes were screened using differential expression analysis, weighted gene co-expression network analysis, and three machine learning algorithms; subsequently, BHLHE40 was evaluated by combining two-sample Mendelian randomization, immune infiltration analysis, gene set enrichment analysis, single-cell transcriptomics, and in vitro overexpression experiments.

Results

A total of 1,928 differentially expressed genes and 34 cellular senescence-related candidate genes were identified. LASSO, SVM-RFE, and random forest collectively identified CXCL12, ENO2, and BHLHE40. In the same combined discovery cohort used for feature selection, BHLHE40 showed an apparent AUC of 0.911. Mendelian randomization analysis suggested a nominal inverse association between genetically predicted circulating BHLHE40 levels and MM risk. Single-cell transcriptomic and ssGSEA analyses further showed that BHLHE40 expression was decreased in MM plasma cells and was associated with relative enrichment scores for selected immune signatures. In vitro experiments showed that BHLHE40 overexpression reduced MM cell viability and EdU incorporation, accompanied by upregulation of p16, p21, and p53 and changes consistent with canonical NF-κB pathway activation (increased p-p65 and decreased IκBα).

Conclusion

Multilevel evidence supports BHLHE40 as a candidate regulator associated with senescence-like growth arrest and immune microenvironment status in MM. Given the lack of external diagnostic cohorts, loss-of-function or rescue experiments, comprehensive senescence phenotyping, and in vivo validation, the current findings are insufficient to establish it as a clinical diagnostic biomarker or therapeutic target.

Zitieren

APA

Pei, Y., Li, P., Pu, Z., Xu, D., & Yang, W. (2026). Integrated bioinformatics and in vitro analyses identify BHLHE40 as a candidate regulator associated with senescence-like growth arrest in multiple myeloma. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1989759

Vancouver

Pei Y, Li P, Pu Z, Xu D, Yang W. Integrated bioinformatics and in vitro analyses identify BHLHE40 as a candidate regulator associated with senescence-like growth arrest in multiple myeloma. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1989759

BibTeX
@article{Pei2026,
  author = {Pei, Yuanyuan and Li, Pinhao and Pu, Zhenhong and Xu, Dan and Yang, Wenxiu},
  title = {Integrated bioinformatics and in vitro analyses identify BHLHE40 as a candidate regulator associated with senescence-like growth arrest in multiple myeloma},
  journal = {Frontiers in Oncology},
  year = {2026},
  volume = {16},
  doi = {10.3389/fonc.2026.1989759}
}
Kostenlos starten →